Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast …

Abemaciclib, tradename Verzenios, in combination with standard endocrine therapy (ET), was appraised within the National Institute for Health and Care Excellence (NICE) Single …

Two years of adjuvant abemaciclib in combination with endocrine therapy (ET) is an internationally approved standard of care with National Comprehensive Cancer Network …

Abemaciclib (Verzenios) has been approved by the National Institute for Health and Care Excellence (NICE) to treat some people with breast cancer that has a high-risk of returning. …

View Abemaciclib [Specialist drug] information, including dose, uses, side-effects and important safety information.

The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Eli Lilly) of abemaciclib (Verzenios) to submit evidence for the clinical and cost effectiveness of this drug …

Abemaciclib in combination with endocrine therapy is the first CDK4/6 inhibitor to be made available within NHS England following the recommendation from NICE for people with HR+, …

Updates from the monarchE and NATALEE trials have reshaped the therapeutic landscape for patients with ER-positive, HER2-negative early-stage breast cancer, giving CDK4/6 inhibitors …

The clinical expert also noted that although abemaciclib can cause diarrhoea and other side effects, these can usually be managed. The committee concluded that abemaciclib plus …

My experience of abemaciclib Caroline Streatfield, who was diagnosed with lobular breast cancer in October 2021, shares her experiences of taking abemaciclib (Verzenio), newly approved by …